Mechano growth factor
Mechano growth factor is a peptide, indexed here under Growth factors and growth hormone-derived compounds.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth factors and growth hormone-derived compounds |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Mechano growth factor is described in a 2010 Endocrinology minireview as a putative product of IGF-I gene expression involved in tissue repair and regeneration. Material sold under this name is the synthetic E-domain peptide; a 2011 Mechanisms of Ageing and Development paper describes the MGF E peptide, derived from an isoform of IGF-1, and its activation of human muscle progenitor cells, and a 2007 Experimental Cell Research paper reports a pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain. PubChem returned no compound record for the name, so the identity fields on this page are unsourced.
Animal and material records include a 2008 Heart, Lung and Circulation paper on loss of cardiac function in acute myocardial infarction, a 2009 Experimental Neurology paper reporting that the IGF-I splice variant rescues motoneurons in SOD1(G93A) mice, a 2011 International Orthopaedics paper on osteoblast proliferation and bone-defect repair in rabbits, a 2015 Biomaterials paper on functionalised silk scaffolds, and a 2014 American Journal of Physiology paper reporting that the peptide had no apparent effect in its stated model.
[2, 3, 4, 5, 6, 7, 8, 9]Reported mechanism
An IGF-I splice variant whose E-domain peptide is reported in the retrieved records to act on muscle progenitor cells; the 2014 American Journal of Physiology record reports no apparent effect in its model, so the mechanism is contested in the retrieved set.
[3, 9]Stated in the titles of the cited 2011 Mechanisms of Ageing and Development and 2014 American Journal of Physiology papers.
Targets named in the cited records: muscle progenitor cells, IGF-1 signalling.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Mechano growth factor appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- MGF
- MGF peptide
- MGF-E peptide
- IGF-1Ec
- PEG-MGF
Where this page sits
Research records
Cited research records for Mechano growth factor, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- IGF-1 LR3 — Growth factors and growth hormone-derived compounds
- IGF-1 DES — Growth factors and growth hormone-derived compounds
- Follistatin-344 — Growth factors and growth hormone-derived compounds
Class page: Growth factors and growth hormone-derived compounds. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Mechano growth factor?
Mechano growth factor is described in a 2010 Endocrinology minireview as a putative product of IGF-I gene expression involved in tissue repair and regeneration. Material sold under this name is the synthetic E-domain peptide; a 2011 Mechanisms of Ageing and Development paper describes the MGF E peptide, derived from an isoform of IGF-1, and its activation of human muscle progenitor cells, and a 2007 Experimental Cell Research paper reports a pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain.
Which class is Mechano growth factor indexed under?
Mechano growth factor is indexed under Growth factors and growth hormone-derived compounds. This class groups the growth factors, growth factor fragments and growth hormone-derived proteins that research-peptide catalogues list alongside the secretagogues, most of which are proteins rather than peptides and are labelled as such on their pages.
What does the FDA application register show for Mechano growth factor?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:mgf
- Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology (2010). pmid:20130113
- Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of ageing and development (2011). pmid:21354439
- A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Experimental cell research (2007). pmid:17156777
- Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart, lung & circulation (2008). pmid:17581790
- Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Experimental neurology (2009). pmid:19038252
- Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. International orthopaedics (2011). pmid:21057789
- Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model. Biomaterials (2015). pmid:25818452
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. American journal of physiology. Endocrinology and metabolism (2014). pmid:24253050
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.